Posterior reversible encephalopathy syndrome (PRES) is a clinicalneuroradiological entity characterized by seizures, headache, altered mental status and visual disturbances associated with typical transient lesions on magnetic resonance imaging (MRI). 1, 2 Allogeneic hematopoietic SCT (allo-HSCT) is associated with a large spectrum of neurological complications including PRES. 3, 4 The prompt recognition of PRES is crucial for starting symptomatic and life-supporting treatment and the proper management of the patient. Until now, a comprehensive assessment of predisposing factors for PRES in transplanted children has never been performed. The aim of this study was to identify the risk factors for PRES in pediatric patients who underwent allo-HSCT.
1
PRES was also associated with a fludarabine-based conditioning regimen, diagnosis of hemoglobinopathy, administration of G-CSF, age 42 years and mismatched unrelated donor, whereas the risk of PRES was lower in immunodeficient patients.
The fludarabine-based regimen was associated with PRES also in a previous report on adult patients. 5 Two patterns of leukoencephalopathy due to the fludarabine-related central nervous system toxicity have been described: PRES and acute toxic leukoencephalopathy. Leukoencephalopathy patterns are based mainly on the anatomic distribution of white matter lesions and different MRI findings. Classical PRES starts from subcortical white matter, whereas acute toxic leukoencephalopathy starts from periventricular white matter. 5 Recently, a high incidence of CYA neurotoxicity, in particular PRES, has been described in pediatric patients transplanted for hemoglobinopathy. 6, 7 In accordance with this observation, we found a high rate of PRES in our cohort for hemoglobinopathy (25.8%) and univariate analysis showed that patients with hemoglobinopathy have a higher risk of PRES.
We also found a very low rate of PRES (1.5%) in transplanted patients with immunodeficiency. Most of these patients (87%) were transplanted at a young age, under 2 years of age at the time of the HSCT, a condition that we found to be a protective factor against the development of PRES. The reasons for the lower incidence of PRES in younger patients transplanted for immunodeficiency should be further investigated.
A higher risk of PRES in patients receiving G-CSF has recently been reported in two cases of stem cell harvesting. 8, 9 Authors hypothesized that the filgrastim-triggered sequence of elevated capillary leakage, circulating neutrophils, the activation of neutrophils through cytokines and the expression of adhesion molecules was followed by the deleterious effects on brain parenchyma.
Calcineurin inhibitors are frequently reported to be associated with PRES. 4, 7, 10 However in our study, calcineurin inhibitors were not identified as a risk factor for PRES. This observation may possibly be due to the small number of patients (14%) who did not receive calcineurin inhibitors as GVHD prophylaxis.
The cumulative incidence of PRES after allo-HSCT (8.3%) is similar to that previously reported in adult reports. 4 Although PRES is typically associated with good clinical outcome, severe complications have been described in association with PRES.
After the diagnosis of PRES, supportive care is the cornerstone of the treatment of patients. When present hypertension and electrolyte imbalance should be promptly corrected. Longer or repeated seizures should be stopped with the use of antiepileptic drugs. In our experience calcineurin inhibitor treatment was stopped and subsequently replaced by a different immunosuppressant agent. In cases of severe complications (that is, hemorrhage, status epilepticus and cerebellar herniation) admission to an intensive care unit may be required to allow a continuous monitoring of vital functions. The main limitation of this study is the retrospective nature of the data collected from database records. This implies that other risk factors potentially influencing the development of PRES, such as hypertension, were not evaluated.
Further studies involving a larger number of patients are needed in a specific pediatric HSCT setting to confirm the role of the identified risk factors for PRES. Letter to the Editor
